Compare Medpace Holdings Inc (MEDP) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Otis Worldwide Corp — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Otis Worldwide Corp trades at $73.5 (market cap $28.20B). The key difference: Otis Worldwide Corp is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.31% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | OTIS | |
|---|---|---|
Market Cap | $15.08B | $28.20B |
Sector | Technology | Industrials |
52-Week High | $620.59 | $100.99 |
52-Week Low | $308.88 | $69.34 |
Enterprise Value | $14.55B | $35.58B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Otis Worldwide trades at $73.49, showing minimal daily movement with a slight 0.05% gain. The stock maintains a bullish technical signal, supported by moving averages, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing estimates despite service growth. The company continues strategic initiatives, including dividend increases and modernization projects, as highlighted in recent corporate announcements.
Outlook remains cautiously optimistic with a consensus price target of $91, offering significant upside. Risks include margin pressures from tariffs and regional delays, but strong service revenue growth and a reasonable valuation provide a foundation for recovery. Investors should weigh near-term headwinds against long-term operational strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
